Business Standard

Monday, December 23, 2024 | 04:38 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Dr Reddy's: Some disappointment in Q4, but generics focus improves outlook

Lower traction in US sales, sequential decline in other key geographies and subdued margin gains disappointed the Street

Drugs, Pharma, medicine
Premium

Ujjval Jauhari
Dr Reddy’s Laboratories (DRL) posted 14 per cent year-on-year (YoY) growth in revenue at Rs 4,016.6 crore and a 44 per cent jump in net profit to Rs 434.3 crore in the March quarter (Q4).

The numbers were ahead of Bloomberg consensus estimates of Rs 3,895 crore and Rs 418 crore, respectively.

However, there were disappointments, too, including below-par US sales in light of contribution from some special products, a sequential decline in sales across other key geographies, and on the gross margins front. 

The overall numbers also included revenue of Rs 180 crore from derma propriety products, which were

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in